Notable Tuesday Option Activity: AMSC, MRNA, CORZ

Large options activity in Moderna and Core Scientific is dominating trading: MRNA saw 101,961 contracts (~10.2M underlying shares, ~98.4% of its 1‑month ADV of 10.4M) led by 10,401 contracts in the $36 call expiring Jan 9, 2026 (~1.0M shares). CORZ printed 98,111 contracts (~9.8M underlying shares, ~92.3% of its 1‑month ADV of 10.6M) with 31,210 contracts in the $18 call expiring Feb 20, 2026 (~3.1M shares). Such concentrated call flows indicate heavy speculative positioning that could drive short‑term price moves and warrant monitoring of gamma/flow-related market impacts.

Analysis

Market structure: The concentrated flow—~10.4k contracts on MRNA $36 Jan‑9‑2026 (~1.0M shares) and ~31.2k contracts on CORZ $18 Feb‑20‑2026 (~3.1M shares) —is large relative to ADV (98% and 92%). That scale will force dealers to delta‑hedge, creating mechanical underlying buying pressure near expiries and pushing short‑term implied volatility higher; tangible price moves of 5–15% in days are plausible if flows are directional.

Risk assessment: Tail risks differ: MRNA faces regulatory/clinical setbacks (FDA decisions, trial readouts) that could erase option premium; CORZ is levered to BTC price, energy costs, and balance‑sheet liquidity (bankruptcy risk if BTC down >50%). Immediate effect (days): gamma squeezes and IV spikes; medium (weeks–months): realized volatility and funding strains; long term: fundamentals reassert (product uptake for MRNA; BTC mining economics for CORZ).

Trade implications: Use defined‑risk option structures rather than outright directional exposure. For MRNA favor buy‑spread or sell premium at elevated IV tails; for CORZ, express directional BTC exposure via call spreads or a long CORZ vs short a stronger miner (e.g., MARA) pair to isolate idiosyncratic upside. Manage size: 1–3% portfolio risk per trade, stop losses at 20–30% of premium.

Contrarian angles: Heavy single‑strike volume can be multi‑leg institutional spreads, not pure buys—don’t assume one‑way conviction. If dealers are already long delta, a quiet expiration can reverse quickly when positions roll. Historical parallels (Tesla gamma runs) show rapid mean reversion after expiry; look for >25% IV divergence vs peers as a tradeable mispricing.

Key Decisions for Investors

• Establish a capped bullish position in MRNA: buy Jan‑9‑2026 $36–$46 call spread sized to 1–2% portfolio risk (max loss = premium). Take profits if MRNA rallies >25% or IV drops >30% from today’s levels; trim if FDA/earnings within 60 days headline negative.
• Speculative asymmetric play in CORZ: buy Feb‑20‑2026 $18–$28 call spreads (or outright $18 calls if liquidity allows) sized to 0.5–1% portfolio. Hedge BTC directional risk by shorting an equal‑delta position in MARA (or RIOT) to create a CORZ‑specific long (target ratio ~1:1 delta), exit if BTC falls >20% in 7 days.
• If neutral to slightly bullish on MRNA fundamentals, sell a small size of short‑dated put credit spreads (e.g., 30–60 day OTM) to collect elevated premium; cap risk with vertical spreads and limit allocation to <1.5% portfolio and close if implied vol rises >40% or stock gap down >10%.
• Monitor three triggers before scaling: (1) FDA/regulatory calendar for MRNA within 30–90 days; (2) BTC spot crossing $50k or moving ±20% in 14 days for CORZ exposure; (3) IV skew divergence >25% versus sector peers — act to unwind or scale into spreads when any trigger is hit.